APT Pharma Raises $32 Million

APT Pharmaceuticals Inc., a Burlingame, Calif.-based developer of inhaled treatments for serious lung diseases, has raised $32.3 million in Series B funding. Three Arch Partners led the round, and was joined by InterWest Partners, Pinnacle Ventures and return backers Charter Life Sciences, Great Point Partners, Versant Ventures and Vivo Ventures. It had previously raised around $33 million.

North AmericaUSBriefs